The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure
NCT ID: NCT00624559
Last Updated: 2012-01-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
12 participants
INTERVENTIONAL
2008-02-29
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of AKB-6548 on the Pharmacokinetics of Celecoxib
NCT02502500
Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition
NCT00780325
Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans
NCT01280006
The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation
NCT01129245
Celecoxib (Celebrex) in the Management of Acute Renal Colic
NCT00304317
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Celebrex; Low sodium
Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
celecoxib (Celebrex)
Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
Celebrex, High Sodium
Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
celecoxib (Celebrex)
Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
Placebo, Low Sodium
Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
Placebo
Placebo pill taken twice per day on each day of the diet
Placebo, High Sodium
Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
Placebo
Placebo pill taken twice per day on each day of the diet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
celecoxib (Celebrex)
Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
Placebo
Placebo pill taken twice per day on each day of the diet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* have had heart surgery
* high blood pressure
* diabetes
* cancer
* any other disease such as kidney or neurological diseases
* taking medications such as aspirin or medicines for your heart or blood pressure
* have asthma or are allergic to sulfa drugs
* body mass index greater than 30
* use tobacco
* pregnant
* women using oral contraceptives or hormone replacement therapy
22 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Christiana Care Health Services
OTHER
University of Delaware
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
William Farquhar
Associate Professor and Department Chair, KAAP
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William B Farquhar, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Delaware
Michael Stillabower, MD
Role: STUDY_DIRECTOR
Christiana Care Health Services
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Delaware
Newark, Delaware, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
134024-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.